Autoimmune liver disease

Current Opinion in Gastroenterology

Volumn 15, Issue 3, 1999, Pages 240-248

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CROSS REACTING ANTIBODY; DRUG METABOLIZING ENZYME; ENDOMYSIUM ANTIBODY; HLA DR ANTIGEN; URSODEOXYCHOLIC ACID;

ADULT; AUTOIMMUNE HEPATITIS; CELIAC DISEASE; CHOLESTASIS; CLINICAL FEATURE; ENDOCRINE DISEASE; GENETIC PREDISPOSITION; GRAFT REJECTION; HEPATITIS; HEPATITIS C VIRUS; HLA SYSTEM; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MOLECULAR MIMICRY; MOUSE; NEEDLESTICK INJURY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; RECURRENT DISEASE; REVIEW; RISK FACTOR; T LYMPHOCYTE; VACCINATION;

EID: 0033029737     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199905000-00009     Document Type: Review

References (35)

1. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103. The first epidemiologic study using current nomenclature and diagnostic techniques in a structured medical system that allows confident tracking of patients.
2. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP: Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997, 92:2197-2200. The first study to compare the HLA risk factors for type 1 autoimmune hepatitis in the United States with type 2 autoimmune hepatitis in Germany and propose a genetic basis for geographic differences in disease occurrence.
3. Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Laudanna AA, Kalil J: Different HLA profiles confer susceptibility to autoimmune hepatitis type 1 and 2. Am J Gastroenterol 1998, 93:1394-1395.
4. Strettell MDJ, Thomson LJ, Donaldson PT, Bunce M, O'Neill CM, Williams R: HLA-C genes and susceptibility to type 1 autoimmune hepatitis. Hepatology 1997, 26:1023-1026. The first study to apply confident assay techniques to assess antigens of the HLA-C locus in type 1 autoimmune hepatitis and propose an association with Cw*0701.
5. Vazquez-Garcia MN, Alaez C, Olivo A, Debaz H, Perez-Luque E, Burguete A, et al.: MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998, 28:985-990.
6. Czaja AJ, Dos Santos RM, Porto A, Santrach PJ, Moore SB: Immune phenotype of chronic liver disease. Dig Dis Sci 1998, 43:2149-2155. Demonstration that HLA-DR4 and the female gender constitute an "immune phenotype" that is host dependent and a basis for concurrent immune disease in all forms of chronic liver disease.
7. Vento S, Cainelli F, Renzini C, Concia E: Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997, 350:1298-1299.
8. Yotsuyanagi H, Koike K, Meng G, Yasuda K, Ogata I, Kimura S, Ohkubo A: Acute exacerbation of autoimmune liver disease associated with hantavirus infection. Scand J Infect Dis 1998, 30:81-83.
9. Czaja AJ, Abdulkarim AS, Carpenter HA, Perez RG, Persing DH, Zein NN: GB virus-C infection in type 1 autoimmune hepatitis. Mayo Clin Proc 1998, 73:412-418.
10. Rosh JR, Dellert SF, Narkewicz M, Birnbaum A, Whitington G: Four cases of severe hepatotoxicity associated with pemotine: Possible autoimmune pathogenesis. Pediatrics 1998, 101:921-923.
11. Newton JL, Burt AD, Park JB, Mathew J, Bassendine MF, James OFW: Autoimmune hepatitis in older patients. Age Ageing 1997, 26:441-444. An alert to clinicians that autoimmune hepatitis in patients older than 65 years is indolent, mild, and frequently untreated despite histologic changes as severe as those in younger counterparts.
12. Kaymakoglu S, Cakaloglu Y, Demir K, Turkoglu S, Badur S, Gurel S, et al.: Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol 1998, 28:78-83. An experience that confirms the similarity of cryptogenic chronic hepatitis and autoimmune hepatitis and further justices a designation of "autoantibody-negative autoimmune hepatitis."
13. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998, 29:198-206.
14. Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C: Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol 1997, 25:538-540.
15. McNair ANB, Moloney M, Portmann BC, Williams R. McFarlane IG: Autoimmune hepatitis overlapping with primary sclerosing cholangitis in 5 cases. Am J Gastroenterol 1998, 93:777-784.
16. Czaja AJ: Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998, 28:360-365. The first effort to define the frequency, nature, and corticosteroid responsiveness of the variant forms of autoimmune liver disease using a scoring system adapted from that proposed by the International Autoimmune Hepatitis Group.
17. Chazouilleres O, Wendum D, Serfaty L, Montebault S, Rosmorduc O, Poupon R: Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology 1998, 28:296-301.
18. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB: Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998, 42:721-726.
19. Parveen S, Morshed SA, Arima K, Nishioka M, Czaja AJ, Chow C, Ng H-S: Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia. Dig Dis Sci 1998, 43:1322-1331.
20. Sjoberg K, Lindgren S, Eriksson S: Frequent occurrence of non-specific gliadin antibodies in chronic liver disease. Scand J Gastroenterol 1997, 32:1162-1167.
21. Volta U, De Franceshi L, Molinaro N, Cassani F, Muratori L, Lenzi M, et al.: Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998, 43:2190-2195. Demonstration of asymptomatic sprue in patients with type 1 and type 2 autoimmune hepatitis that was discovered by screening for endomysial antibodies.
22. Chen M, Shirai M, Czaja AJ, Kurokohchi K, Arichi T, Arima K, et al.: Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998, 13:483-489.
23. Manns MP, Obermayer-Straub P: Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: Model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997, 26:1054-1066. A comprehensive review of the antigenic role of drug-metabolizing enzymes in immune-mediated chronic liver diseases that are characterized by LKM antibodies.
24. Wesierska-Gadek J, Grimm R, Hitchman E, Penner E: Members of the glutathione S-transferase gene family are antigens in autoimmune hepatitis. Gastroenterology 1998, 114:329-335.
25. Miyachi K, Matsushima H, Hankins RW, Hirakata M, Mimori T, Hosaka H, et al.: A novel antibody detected against a three-dimensional configuration of a 95-kDa protein in patients with autoimmune hepatic diseases. Scand J Immunol 1998, 47:63-68.
26. Clemente MG, Meloni A, Obermayer-Staub P, Frau F, Manns MP, De Virgiliis S: Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998, 114:324-328.
27. Arenz M, Meyer zum Buschenfelde K-H, Lohr HF: Limited T cell receptor Vβ-chain repertoire of liver infiltrating T cells in autoimmune hepatitis. J Hepatol 1998, 28:70-77.
28. Bayer EM, Herr W, Kanzler S, Waldmann C, Meyer zum Buschenfelde K-H, Dienes HP, et al.: Transforming growth factor-β1 in autoimmune hepatitis: Correlation of liver tissue expression and serum levels with disease activity. J Hepatol 1998, 28:803-811. Recognition that TGF-β1 is commonly present in liver tissue in the absence of clinical features of residual disease activity and that it may be a basis for ongoing fibrogenesis during apparent remission of the disease.
29. Choudhuri K, Gregorio GV, Mieli-Vergani G, Vergani D: Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis. Hepatology 1998, 28:1177-1181. Interesting report speculating that molecular mimicry and autoantibody cross-reactivity between the second major epitope of type 2 autoimmune hepatitis and the autoantigens of insulin-dependent diabetes mellitus and Addison's disease contribute to the appearance of these endocrinopathies in the liver disease.
30. Lohse AW, Dienes HP, Meyer zum Buschenfelde K-H: Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998, 27:1536-1543. Evaluation of a novel method for attenuating autoreactivity in experimental autoimmune hepatitis that has exciting potential not only in disease prevention but also in therapy.
31. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, et al.: Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998, 13:490-495.
32. Sempoux C, Horsmans Y, Lerut J, Rahier J, Geubel A: Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver 1997, 17:311-315.
33. Hayashi M, Keeffe EB, Krams SM, Martinez OM, Ojogho ON, So SKS, et al.: Allograft rejection after liver transplantation for autoimmune liver disease. Liver Transplant Surg 1998, 4:208-214.
34. Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, et al.: De-novo autoimmune hepatitis after liver transplantation. Lancet 1998, 353:409-413. Recognition that autoreactivity can be acquired after liver transplantation in children, possibly because immunosuppressive therapy interferes with T-lymphocyte maturation and facilitates the emergence of autoreactive clones.
35. Sawada K, Ohnishi K, Kosaka T, Chikano S, Egashira A, Okui M, et al.: Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy. J Gastroenterol 1997, 32:689-695.